9.2 Protocol Review and Monitoring System (PRMS) Overview Effective expansion of the DF/HCC clinical research capability is dependent upon a fully integrated clinical trials infrastructure serving oncology research efforts. The Protocol Review and Monitoring System (PRMS), which oversees the scientific design and progress of DF/HCC clinical trials, is a critical component of that effort as it ensures that new protocols are important, well designed and are feasible within a reasonable timeframe. The PRMS system includes: ? The initial scientific development and review that is performed through the Disease Programs; ? The formal evaluation for merit, feasibility and priority that is performed by the centralized Scientific Review Committee;and ? The oversight for scientific process and data quality assurance that is performed by the Clinical Investigations Policy and Oversight Committee (CLINPOC). With the integration of BIDMC and consequently an expansion of our clinical trials to additional investigators and protocols, PRMS now assures scientific quality for all recently activated BIDMC research oncology protocols as well. The current operational scheme for clinical trial development, approval, activation, and support is shown in Appendix 2 included at the end of section 9.1.14, CROC. Each of these components has been described in the preceding section on CROC and will be illustrated in more detail below. The process for the scientific review of new and active protocols will be highlighted in the initial portions of this section. Once these systems have been described, the results of scientific review and oversight will be presented.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-46
Application #
8038409
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
46
Fiscal Year
2010
Total Cost
$46,400
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583

Showing the most recent 10 out of 411 publications